Leucemia linfatica cronica

LLC1415 A retrospective study to evaluate the clinic-biologic characteristics and outcome of patients treated in Italy according to the Ibrutinib-Named Patient Program (NPP) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL)

CLL-FITNESS STUDY A multi center retrospective observational study of the criteria applied in clinical practice to decide first-line treatment for Chronic Lympocytic Leukemia (CLL) patients

LLC1114 Studio multicentrico di fase 2 per valutare attività e sicurezza della terapia di prima linea con Ibrutinib in associazione a Rituximab (IR) in pazienti unfit con Leucemia Linfatica Cronica (LLC)

IMPROVE Multi-Center, Open Label, Uncontrolled, Phase 2a Clinical Trial Evaluating the Safety and Efficacy of the Addition of Ibrutinib to Venetoclax through a MRD-guided Approach in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia (CLL).

CC5013CLL002 Studio di fase 3, multicentrico, randomizzato, in doppio cieco, controllato verso placebo, a gruppi paralleli, sull’efficacia e la sicurezza di lenalidomide (REVLIMID®) somministrata come terapia di mantenimento in pazienti con Leucemia Linfocitica Cronica a Cellule B dopo terapia di seconda linea.

CLLM1 A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lenalidomide (Revlimid®) as maintenance therapy for high-risk patients with chronic lymphocytic leukemia following first-line therapy

IPI 145-07 A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

LLC1315 An observational study to assess the efficacy and safety of Bendamustine plus Rituximab in patients affected by Chronic Lymphocytic Leukemia.

GO28667 Studio multicentrico di fase 3, in aperto, randomizzato, in pazienti affetti da leucemia linfocitica cronica recidivante/refrattaria per valutare i benefici di GDC-0199 (ABT-199) piÙ rituximab rispetto a bendamustina più rituximab

PCYC1112CA A Randomized, Multicenter, Open-Label, Phase 3 Study ofthe Bruton's Tyrosine Kinase (BTK) lnhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PCYC1115CA A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PCYC1116CA An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 versus Chlorambucil)

PCYC1142CA Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma